Repros Therapeutics (RPRX) Tops Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Repros Therapeutics Inc.(R) Reports Third Quarter 2014 Financial Results
November 10, 2014 9:03 AM ESTTHE WOODLANDS, Texas, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq: RPRX) today announced financial results for the third quarter ended September 30, 2014.
Financial Results
Net loss for the three month period ended September 30, 2014, was ($7.4) million or ($0.32) per share as compared to a net loss of ($6.0) million or ($0.26) per share for the same period in 2013. The net loss for the nine month period ended September 30, 2014, was ($24.6) million or ($1.06) per share as compared to a net loss of ($20.6) million or ($1.03) per share for the same period in 2013. The increases in net... More
